From April 27 to 28, the 111th Annual Meeting of the American Association for Cancer Research (AACR) in 2020 was held. It is one of the oldest and largest academic conferences on cancer research in the world. At the "Phase Ⅱ Clinical Trials" on April 27, Prof. Lu Shun from Shanghai Chest Hospital, an affiliated hospital of Shanghai Jiao Tong University, gave an oral report on the latest Phase II clinical research results of AMEILE (Almonertinib Mesilate Tablets), a Class 1 innovative drug independently developed by Hansoh Pharma, in patients with epidermal growth factor receptor (EGFR) T790M mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), and disclosed the efficacy on lung cancer patients with brain metastasis, which have aroused widespread attention in the oncology community. This is another influential voice of China's original drug Almonertinib on the international stage after its debut at the 2019 World Conference on Lung Cancer (WCLC).
At the AACR Annual Meeting, Prof. Lu Shun released the efficacy and safety data of Almonertinib from Phase II clinical trials followed up to August 1, 2019, and for the first time, the efficacy data of patients with brain metastasis. The data showed that at the median follow-up time of 11.8 months, the second-line treatment with Almonertinib for NSCLC patients with positive EGFR T790M mutation was effective. According to the evaluation of the independent evaluation committee, the efficacy of Almonertinib in patients with brain metastasis is similar to that in the general population. With the extension of follow-up time, the long-term safety of Almonertinib has been further verified, with low incidence of adverse events, no occurrence of interstitial pneumonia and good safety.
Relying on its advanced innovative drug research and development system, Hansoh Pharma has been making breakthroughs in the efficacy and safety of drugs through innovation. AMEILE (Almonertinib Mesilate Tablets) was approved for marketing by the National Medical Products Administration (NMPA) in March 2020, which provides clinicians with a highly efficacious, safe and accessible new option of drug, and brings hope for long-term and high-quality survival to more patients with advanced non-small cell lung cancer (NSCLC). Following the 2019 World Conference on Lung Cancer (WCLC), AMEILE has twice appeared on the international stage, fully demonstrating the strength and influence of Chinese innovative drugs in scientific research and technological innovation.
After years of R&D and exploration, four Class 1 innovative drugs of Hansoh Pharma have been approved for marketing, specifically: AMEILE (Almonertinib Mesilate Tablets), the new second-generation drug HAOSENXINFU (Flumatinib Mesylate Tablets) for chronic myeloid leukemia (CML), the hypoglycemic drug FULAIMEI (Polyethylene Glycol Loxenatide Injection) that requires only one injection per week, and the latest-generation anti-anaerobic drug MAILINGDA (Morinidazole and Sodium Chloride Injection), which have brought more better drug choices for the vast number of doctors and patients.
As a leading innovation-driven pharmaceutical company in China, Hansoh Pharma will live up to its corporate mission to "create excellence in pharmaceuticals, enhance innovation in China", adhere to the patient benefits centered philosophy, accelerate the pace of scientific and technological innovation, and contribute to the society with more, newer and better innovative drugs, so as to bring health and well-being to patients in China and the world.
About AMEILE (Almonertinib Mesilate Tablets)
AMEILE (Almonertinib Mesilate Tablets) is the world's second 3rd-generation EGFR TKI innovative drug independently developed by Hansoh Pharma, and also the world's first 3rd-generation EGFR TKI with a median progression-free survival (mPFS) of more than 1 year (second-line use), for the treatment of "adult patients who have progressed on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy, with T790M mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)".
About Hansoh Pharma
Founded in 1995, Jiangsu Hansoh Pharmaceutical Group Co., Ltd. ("Hansoh Pharma") is a leading R&D-driven pharmaceutical company in China. Adhering to its corporate mission to "create excellence in pharmaceuticals, enhance innovation in China", Hansoh Pharma has been committed to improving human health through continuous innovation, especially in major disease treatment fields including CNS, oncology, anti-infectives, diabetes, gastrointestinal and cardiovascular diseases. For many years in a row, the company has been ranked in the top 30 of "China’s Top 100 Pharmaceutical Industrial Enterprises" and in the top 3 of "China’s Best Industrial Enterprises in Pharmaceutical R&D Pipeline". It is also a national key high-tech enterprise and a national technology innovation demonstration enterprise. The company was listed on the Hong Kong Stock Exchange in June 2019 (HK.03692).
About AACR Annual Meeting
The American Association for Cancer Research (AACR) Annual Meeting is one of the oldest and largest academic conferences on cancer research in the world. Focusing on all aspects of high-quality cancer research and innovation, the meeting is a global focal point for cancer research, bringing together the most cutting-edge findings in the field of cancer. Affected by the COVID-19, this year's AACR annual meeting was held online.
